Fig. 2

BMSCs were induced to acquire fibrotic phenotype by bleomycin in vitro. a, b BMSCs were pretreated with TGFβR1 inhibitor LY364947(10 μM) or DMSO and stimulated with bleomycin in a concentration of 0, 5, and 10 μg/ml, then cells were cultured for 48 h and observed in a checkpoint of 0, 24 h, and 48 h to calculate the migration rate by wound healing assay or cultured for 24 h to do the transwell test. c BMSCs were stimulated with bleomycin in different concentrations of 0, 5, and 10 μg/ml in 24 and 48 h, following cell viability analysis using Cell Count Kit-8 and then subsequently calculated with Graphpad8.0 by ordinary one-way ANOVA test. d Western blot analysis of TGFβR1, FSP1, and Col1a1 in BMSCs uses β-actin as a reference. e Immunofluorescence assay of TGFβ and Col1a1 in the BMSCs. f Q-PCR analysis of the relative mRNA expression levels of TGFβ, TGFβR1, Fn1, FSP1, and Col1a1 in BMSCs with bleomycin. All data are presented as mean ± sd. from three experiments. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001